Nitrogen-containing Heterocyclic quinones: A class of potential selective antitumor agents

被引：79

作者：

Garuti, Laura ^{[1
]}

Roberti, Marinella ^{[1
]}

Pizzirani, Daniela ^{[1
]}

机构：

[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2007年 / 7卷 / 05期

关键词：

quinones; anticancer agents; tumor-selective toxicity; SAR; prodrugs; heterocycles; CYTOTOXICITY IN-VITRO; INDOLEQUINONE PHOSPHORAMIDATE PRODRUGS; DT-DIAPHORASE; CELL-CYCLE; BIOLOGICAL EVALUATION; NAD(P)H-QUINONE OXIDOREDUCTASE; CDC25; PHOSPHATASES; TOPOISOMERASE-II; CANCER-THERAPY; ANTIPROLIFERATIVE ACTIVITY;

D O I：

10.2174/138955707780619626

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The development of prodrugs that are enzymatically activated into anticancer agents is a promising perspective in cancer therapy. Many nitrogen-containing quinoid heterocycles have been reported to show antitumor effect. The principal interest in these compounds lies on their potential to produce tumor-selective toxicity. Selectivity occurs by difference in oxygen tension between normal and tumor tissue and by levels of the required activating enzymes.

引用

页码：481 / 489

页数：9

共 98 条

[1]

[Anonymous], DRUG DES REV

[2] Antitumour quinones [J].

Asche, C .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (05) :449-467

[3] Synthesis and structure-activity relationships of 1,5-diazaanthraquinones as antitumour compounds [J].

Avendaño, C ;

Pérez, JM ;

Blanco, MD ;

de la Fuente, JA ;

Manzanaro, S ;

Vicent, MJ ;

Martín, MJ ;

Salvador-Tormo, N ;

Menéndez, JC .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (15) :3929-3932

[4] Indolequinone antitumor agents: Relationship between quinone structure and rate of metabolism by recombinant human NQO1 [J].

Beall, HD ;

Hudnott, AR ;

Winski, S ;

Siegel, D ;

Swann, E ;

Ross, D ;

Moody, CJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (05) :545-548

[5] Mechanisms of action of quinone-containing alkylating agents I: NQO1-directed drug development [J].

Beall, HD ;

Winski, SL .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2000, 5 :D639-D648

[6] Indolequinone antitumor agents:: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity [J].

Beall, HD ;

Winski, S ;

Swann, E ;

Hudnott, AR ;

Cotterill, AS ;

O'Sullivan, N ;

Green, SJ ;

Bien, R ;

Siegel, D ;

Ross, D ;

Moody, CJ .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (24) :4755-4766

[7] BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity [J].

Beggiolin, G ;

Crippa, L ;

Menta, E ;

Manzotti, C ;

Cavalletti, E ;

Pezzoni, G ;

Torriani, D ;

Randisi, E ;

Cavagnoli, R ;

Sala, F ;

Giuliani, FC ;

Spinelli, S .

TUMORI, 2001, 87 (06) :407-416

[8] The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase α is mediated by hydrogen peroxide [J].

Bova, MP ;

Mattson, MN ;

Vasile, S ;

Tam, D ;

Holsinger, L ;

Bremer, M ;

Hui, T ;

McMahon, G ;

Rice, A ;

Fukuto, JM .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2004, 429 (01) :30-41

[9] Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases [J].

Brezak, MC ;

Quaranta, M ;

Contour-Galcera, MO ;

Lavergne, O ;

Mondesert, O ;

Auvray, P ;

Kasprzyk, PG ;

Prevost, GP ;

Ducommun, B .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) :1378-1387

[10] Redox regulation of Cdc25B by cell-active quinolinediones [J].

Brisson, M ;

Nguyen, T ;

Wipf, P ;

Joo, B ;

Day, BW ;

Skoko, JS ;

Schreiber, EM ;

Foster, C ;

Bansal, P ;

Lazo, JS .

MOLECULAR PHARMACOLOGY, 2005, 68 (06) :1810-1820

← 1 2 3 4 5 6 7 8 9 10 →